Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - ApoGen Biotechnologies

Next Previous
Search
Drug Profile

Research programme: cancer therapeutics - ApoGen Biotechnologies

Latest Information Update: 28 Apr 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ApoGen Biotechnologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cytidine deaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Apr 2021 No recent reports of development identified for research development in Cancer in USA
  • 16 Apr 2019 9208785: As per the MR the company is also working to develop companion diagnostics to identify the patients likely to get the most benefit from these therapies. Separate profile required for the companion diagnostic programme. As of now dormated the diagnosis dev line and changed the AN
  • 12 Dec 2016 ApoGen Biotechnologies in-licenses APOBEC technology from University of Minnesota

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top